Cargando…

Early detection of pre-malignant lesions in a KRAS(G12D)-driven mouse lung cancer model by monitoring circulating free DNA

Lung cancer is the leading cause of cancer-related death. Two-thirds of cases are diagnosed at an advanced stage that is refractory to curative treatment. Therefore, strategies for the early detection of lung cancer are urgently sought. Total circulating free DNA (cfDNA) and tumour-derived circulati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rakhit, Callum P., Trigg, Ricky M., Le Quesne, John, Kelly, Michael, Shaw, Jacqueline A., Pritchard, Catrin, Martins, L. Miguel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Company of Biologists Ltd 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398498/ https://www.ncbi.nlm.nih.gov/pubmed/30760495 http://dx.doi.org/10.1242/dmm.036863

Ejemplares similares

Opportunities and challenges of circulating biomarkers in neuroblastoma
por: Trigg, Ricky M., et al.
Publicado: (2019)

Diagnostic accuracy of circulating-free DNA for the determination of MYCN amplification status in advanced-stage neuroblastoma: a systematic review and meta-analysis
por: Trigg, Ricky M., et al.
Publicado: (2020)

KRAS-driven ROS promote malignant transformation
por: Suh, Yongjoon, et al.
Publicado: (2015)

Challenges in detecting pre-malignant pancreatic lesions during acute pancreatitis using a serum microRNA assay: a study based on Kras(G12D) transgenic mice
por: Hong, Xiafei, et al.
Publicado: (2016)

Identification of KRAS(G12C) Mutations in Circulating Tumor DNA in Patients With Cancer
por: Thein, Kyaw Z., et al.
Publicado: (2022)

Iron out KRAS-driven cancer
por: Lei, Guang, et al.
Publicado: (2022)

The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer
por: Ghaddar, Nour, et al.
Publicado: (2021)

MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways
por: Patel, Asmita, et al.
Publicado: (2014)

Combined KRAS(G12C) and SOS1 inhibition enhances and extends the anti-tumor response in KRAS(G12C)-driven cancers by addressing intrinsic and acquired resistance
por: Thatikonda, Venu, et al.
Publicado: (2023)

Hypothalamic beta-endorphin neurons suppress preneoplastic and neoplastic lesions development in 1,2-dimethylhydrazine induced rat colon cancer model
por: Murugan, Sengottuvelan, et al.
Publicado: (2017)

Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors
por: Stites, Edward C., et al.
Publicado: (2018)

Twists and turns in Kras-driven tumor initiation
por: Maru, Yoshiaki, et al.
Publicado: (2021)

Reduced HRAS(G12V)-Driven Tumorigenesis of Cell Lines Expressing KRAS(C118S)
por: Huang, Lu, et al.
Publicado: (2015)

KRAS signaling in malignant pleural mesothelioma
por: Marazioti, Antonia, et al.
Publicado: (2021)

Salivary copper and zinc levels in oral pre-malignant and malignant lesions
por: Ayinampudi, Bhargavi Krishna, et al.
Publicado: (2012)

Fbxw7 Deletion Accelerates Kras(G12D)-Driven Pancreatic Tumorigenesis via Yap Accumulation()()()
por: Zhang, Qiang, et al.
Publicado: (2016)

The Inhibition of Wnt Restrain KRAS(G12V)-Driven Metastasis in Non-Small-Cell Lung Cancer
por: Hung, Pei-Shan, et al.
Publicado: (2020)

Inactivation of Rbx1 E3 ligase suppresses Kras(G12D) ‐driven lung tumorigenesis
por: Li, Yanan, et al.
Publicado: (2023)

UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma
por: Kostyrko, Kaja, et al.
Publicado: (2023)

Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers
por: Arner, Emily N., et al.
Publicado: (2019)

Brown Tumors Belong to the Spectrum of KRAS-driven Neoplasms
por: Turek, Daniel, et al.
Publicado: (2022)

Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer
por: Wang, Man-Tzu, et al.
Publicado: (2019)

Mitochondria-Targeted Antioxidants MitoQ and MitoTEMPO Do Not Influence BRAF-Driven Malignant Melanoma and KRAS-Driven Lung Cancer Progression in Mice
por: Le Gal, Kristell, et al.
Publicado: (2021)

Circadian disruption enhances HSF1 signaling and tumorigenesis in Kras-driven lung cancer
por: Pariollaud, Marie, et al.
Publicado: (2022)

Critical requirement of SOS1 for tumor development and microenvironment modulation in KRAS(G12D)-driven lung adenocarcinoma
por: Baltanás, Fernando C., et al.
Publicado: (2023)

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine
por: Pan, Jing, et al.
Publicado: (2017)

Targeting copper metabolism to defeat KRAS-driven colorectal cancer
por: Aubert, Léo, et al.
Publicado: (2020)

Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers
por: Hyun, Soonsil, et al.
Publicado: (2021)

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS(G12D) or KRAS(G12V) mutations
por: Kun, Eucharist H. S., et al.
Publicado: (2020)

KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy
por: Ryan, Meagan B., et al.
Publicado: (2022)

BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer
por: Ohnami, Shumpei, et al.
Publicado: (2021)

Factors that influence quality and yield of circulating-free DNA: A systematic review of the methodology literature
por: Trigg, R.M., et al.
Publicado: (2018)

Loss of Canonical Smad4 Signaling Promotes KRAS Driven Malignant Transformation of Human Pancreatic Duct Epithelial Cells and Metastasis
por: Leung, Lisa, et al.
Publicado: (2013)

Core regulatory circuitries in defining cancer cell identity across the malignant spectrum
por: Jahangiri, Leila, et al.
Publicado: (2020)

Biopsy strategies for endoscopic screening of pre-malignant gastric lesions
por: Zhang, Meng, et al.
Publicado: (2019)

Acinar-to-Ductal Metaplasia Induced by Transforming Growth Factor Beta Facilitates KRAS(G12D)-driven Pancreatic Tumorigenesis
por: Chuvin, Nicolas, et al.
Publicado: (2017)

Oncogenic KRAS promotes malignant brain tumors in zebrafish
por: Ju, Bensheng, et al.
Publicado: (2015)

Mutant KRAS promotes malignant pleural effusion formation
por: Αgalioti, Theodora, et al.
Publicado: (2017)

PTPN2 regulates the activation of KRAS and plays a critical role in proliferation and survival of KRAS-driven cancer cells
por: Huang, Zhangsen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h3fjdbmnf1ajideln0sr66hafp